HPLC purity
Reverse-phase HPLC with UV detection; purity target reported per lot with related-substance reporting on request.
CJC-1295 with DACHPLC ≥ 99%MS confirmed2mg
Vial illustrations reflect supplied lyophilized format. Distribution scope and destination market confirmed before invoicing.
| Compound | CJC-1295 with DAC |
|---|---|
| CAS number | 446262-90-4 |
| Molecular formula | C165H269N47O46 |
| Molecular weight | 3647.2 g/mol |
| Sequence | Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys(ε-maleimidopropionyl)-NH2 |
| Form | Lyophilized powder, glass vial |
| Purity target | ≥ 99% by HPLC |
| Vial formats | 2mg / 5mg / 10mg |
| Documentation | Batch-linked COA + HPLC chromatogram + MS identity record for every production lot |
| Distribution scope | Research use, worldwide |
| Storage | Store lyophilized powder at -20°C, protected from light and moisture; short-term handling at 2-8°C is acceptable. After reconstitution, keep at 2-8°C and use within a limited window; avoid repeated freeze-thaw. Ships with cold-chain / ice-pack packaging. |
MOQ & lead time
| Tier | Quantity | Lead time |
|---|---|---|
| Sample lot | 1 kit (10 vials) | 3–7 days |
| Production lot | 200–1,000 vials | 10–14 days |
| OEM repeat | 1,000+ vials | 14–18 days, scheduled |
Supplied as a research-use peptide. Every quote confirms current-batch COA, purity, destination market and buyer track before invoicing.
Overview
About CJC-1295 with DAC.
CJC-1295 with DAC is a synthetic 30-residue analog of growth hormone-releasing hormone (GHRH 1-29) bearing four stabilizing substitutions ([D-Ala2, Gln8, Ala15, Leu27]) plus a C-terminal lysine functionalized with a maleimidopropionyl group known as the Drug Affinity Complex (DAC). In research models the maleimide moiety forms a covalent bond with circulating serum albumin, markedly prolonging plasma residence and GHRH-receptor exposure relative to non-DAC GHRH analogs such as Mod GRF (1-29).
Documentation
Batch documentation support for CJC-1295 with DAC lots.
batch-linked COA, HPLC chromatogram and MS identity record for every production lot. Distribution scope confirmed before invoicing.
MS identity
Mass spectrometry identity confirmation against the CJC-1295 with DAC reference profile.
Lot traceability
Compound prefix and lot serial printed on the vial label and repeated in the document pack and carton.
FAQ
CJC-1295 with DAC — frequently asked by B2B buyers.
What vial sizes and MOQ does Pepti offer for CJC-1295 with DAC?
We supply CJC-1295 with DAC as a lyophilized research-use powder in 2 mg, 5 mg and 10 mg vials, with a minimum order quantity of 1 kit (10 vials). Larger bulk quantities and custom fill weights are available on RFQ.
How is purity and identity documented?
Every production lot includes a batch-linked COA reporting the actual HPLC purity result, plus HPLC chromatogram and MS identity record. Production lots target ≥99% HPLC purity unless a special RFQ specification is agreed.
How does CJC-1295 with DAC differ from CJC-1295 without DAC (Mod GRF 1-29)?
Both share the same [D-Ala2, Gln8, Ala15, Leu27] GHRH(1-29) backbone, but the DAC version adds a C-terminal lysine bearing a maleimidopropionyl group that covalently binds serum albumin in research models, substantially extending circulating half-life. The non-DAC variant lacks this albumin-binding moiety and clears far more rapidly.
What private-label and OEM options are available?
Pepti provides custom vial labeling, kit configuration, and documentation packages for private-label brands and distributors. Reconstitution ancillaries such as bacteriostatic water can be bundled into finished kits on request.
What are the compliance and intended-use restrictions?
CJC-1295 with DAC is supplied strictly for laboratory and research use, not for consumer or veterinary consumption. Buyers are responsible for meeting import, licensing, and regulatory requirements in their destination market.
Related compounds